Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Issued (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Shares Issued for 10 consecutive years, with $323000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 100.26% to $323000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $323000.0, a 72.6% decrease, with the full-year FY2025 number at $323000.0, down 72.6% from a year prior.
  • Shares Issued was $323000.0 for Q4 2025 at Cartesian Therapeutics, up from -$183000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $121.6 million in Q3 2024 to a low of -$123.3 million in Q4 2024.
  • A 4-year average of $3.2 million and a median of $168500.0 in 2024 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: crashed 133.58% in 2021, then skyrocketed 6001.66% in 2022.
  • Cartesian Therapeutics' Shares Issued stood at -$674000.0 in 2021, then skyrocketed by 5549.85% to $36.7 million in 2022, then crashed by 435.56% to -$123.3 million in 2024, then soared by 100.26% to $323000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Shares Issued are $323000.0 (Q4 2025), -$183000.0 (Q2 2025), and $183000.0 (Q1 2025).